Terms: = Prostate cancer AND FBXO11, MGC44383, 80204, ENSG00000138081, Q86XK2, VIT1, UG063H01, PRMT9, FLJ12673, FBX11
5 results:
1. Elucidating the role of PRMTs in prostate cancer using open access databases and a patient cohort dataset.
Grypari IM; Pappa I; Papastergiou T; Zolota V; Bravou V; Melachrinou M; Megalooikonomou V; Tzelepi V
Histol Histopathol; 2023 Mar; 38(3):287-302. PubMed ID: 36082942
[TBL] [Abstract] [Full Text] [Related]
2. Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome.
Salo-Mullen EE; Lynn PB; Wang L; Walsh M; Gopalan A; Shia J; Tran C; Man FY; McBride S; Schattner M; Zhang L; Weiser MR; Stadler ZK
Fam Cancer; 2018 Jan; 17(1):71-77. PubMed ID: 28555354
[TBL] [Abstract] [Full Text] [Related]
3. Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression.
Ngollo M; Lebert A; Daures M; Judes G; Rifai K; Dubois L; Kemeny JL; Penault-Llorca F; Bignon YJ; Guy L; Bernard-Gallon D
BMC Cancer; 2017 Apr; 17(1):261. PubMed ID: 28403887
[TBL] [Abstract] [Full Text] [Related]
4. PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening.
Zhu S; Xu Y; Song M; Chen G; Wang H; Zhao Y; Wang Z; Li F
Mol Med Rep; 2016 Oct; 14(4):3357-61. PubMed ID: 27511603
[TBL] [Abstract] [Full Text] [Related]
5. The oncogenic microRNA-21 inhibits the tumor suppressive activity of fbxo11 to promote tumorigenesis.
Yang CH; Pfeffer SR; Sims M; Yue J; Wang Y; Linga VG; Paulus E; Davidoff AM; Pfeffer LM
J Biol Chem; 2015 Mar; 290(10):6037-46. PubMed ID: 25589783
[TBL] [Abstract] [Full Text] [Related]
